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Background: The impact of patient-prosthesis mismatch (PPM) on early outcomes in young and middle-aged
patients undergoing conventional aortic valve replacement for severe aortic stenosis remains unknown. Our
objective was to evaluate the incidence of some degree of PPM and its influence on early mortality and morbidity.
Methods: We analyzed our single center experience in all patients <70 years undergoing first-time isolated aortic
valve replacement for severe stenosis in our center from September 2007 to September 2011. PPM was defined as
an indexed effective orifice area≤ 0,85 cm2/m2. The influence of PPM on early mortality and postoperative
complications was studied using propensity score analysis. Follow up at 30 postoperative days was 100% complete.
Results: Of 199 patients studied, 61 (30,7%) had some degree of PPM. PPM was associated with an increased
postoperative mortality (OR = 8,71; 95% CI = 1,67–45,29; p= 0,04) and major postoperative complications (OR = 2,96;
CI = 1,03–8,55; p= 0,044). However, no association between PPM and prolonged hospital or ICU stay was
demonstrated.
Conclusions: Moderate PPM is a common finding in young and middle-aged patients undergoing surgery for
aortic valve replacement due to severe stenosis. In addition, its influence on early outcomes may be relevant.
Keywords: Patient-prosthesis mismatch, Severe aortic stenosisBackground
Aortic stenosis is the most common valvular heart dis-
ease and the third most common cardiovascular disorder
after hypertension and coronary artery disease in the
developed world [1]. Left ventricular hypertrophy caused
by severe aortic stenosis (SAS) is associated with sudden
death, congestive heart failure and stroke [2]. Aortic
valve replacement (AVR) has been shown to change the
natural history of these patients [1] reducing the pres-
sure gradient between the left ventricle and ascending
aorta and reversing left ventricular remodeling. However,
if some degree of residual aortic stenosis remains after
replacement reverse remodeling may be compromised.* Correspondence: dhvaquero@gmail.com
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use, distribution, and reproduction in any medPatient-prosthesis mismatch (PPM) after an AVR was
first defined by Rahimtoola [3] as the situation in which
the effective area of a well-functioning prosthetic valve is
less than that of a normal human valve. However, despite
the almost 35 years since its original description, the con-
cept and impact of PPM remains highly controversial.
Whereas some researchers have reported a lower post-
operative survival rate among patients with PPM [4,5],
others have not observed these adverse results [6,7].
Given this situation, it has been recently suggested
that the impact of PPM on outcomes depends on base-
line patient characteristics. Accordingly, some studies
[8,9] have revealed that PPM has a significant negative
effect on long-term survival of patients< 70 years old
but not in the elderly.
Moreover, ventricular performance and hemodynamic
status are more vulnerable during the early postoperative
period when the increased afterload induced by PPMsee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
Table 1 In vivo effective orifice area values corresponding
to each valve
Prosthetic valve 19 mm 21 mm 23 mm 25 mm Reference
Mechanical
St Jude M Regent 1,6 (22) 2 (42) 2,2 (26) 2,5 (17) [12]
Carbomedics 1 (1) 1,5 (9) 1,6 (22) 2 (11) [13]
Carbomedics Top Hat 1,1 (4) 1,2 (4) 1,4 (16) 1,6 (0) [14]
MCRI On-X 1,5 (2) 1,7 (0) 2 (1) 2,4 (0) [15]
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postoperative mortality [2].
However, at our knowledge no previous reports have
investigated the incidence and the impact of PPM on
mortality and morbidity during the first 30 postoperative
days in patients under 70 years after conventional AVR.
For this purpose, we studied a consecutive series of that
subgroup of patients who underwent isolated first-time
AVR for SAS in our center.Bioprosthesis
Mitroflow 1,2 (3) 1,4 (10) 1,6 (7) (0) [16]
Labcor (0) 1,1 (1) 1,4 (0) 1,5 (0) [17]
In parentheses, the number of patients with that valve in our series.Methods
Patient population and data collection
Between September 2007 and September 2011, 199 patients
> 18 and< 70 years old underwent isolated first-time AVR
for SAS with or without some degree of associated aortic
regurgitation in the Cardiac Surgery Department of the
Hospital Universitario Central de Asturias (Oviedo, Spain).
To avoid a heterogeneous series, patients with significant
coronary artery disease, those with previous percutaneous
coronary interventions, or those who required concomitant
mitral or tricuspid valve surgery or ascending aorta replace-
ment were excluded.
Coronary angiography and transthoracic echocardiog-
raphy were performed in all patients within the 12 and
6 months prior to the intervention respectively. Clinical,
operative, and outcomes data were prospectively collected
and validated. Database was queried retrospectively. All
discharged patients were clinically assessed one month
after the operation in our outpatient clinic. Follow-up at
30 postoperative days was 100% complete. The study was
approved by the regional ethics committee.Definition of PPM and study end-points
PPM was defined as the indexed effective orifice area
(IEOA) ≤ 0,85 cm2/m2 and was considered severe when
the IOEA was ≤ 0,65 cm2/m2 [10,11]. To calculate the
IEOA we divided between the in vivo EOA measure-
ments for each prosthesis and the body surface area
(BSA) which was calculated using the Dubois formula
[6]. We used the data published for the in vivo EOA
values [12-17] (Table 1) due to its ability to predict the
postoperative gradients [4,18,19], whereas ex-vivo mea-
surements reported by manufacturers overestimate the
true prosthetic valve EOA [13,18], and consequently, re-
sult in a low sensitivity for the prediction of PPM [11].
We analyzed the influence of PPM on 30 day mortality
and postoperative complications. For statistical power en-
hancement, postoperative complications were pooled into
major complications: postoperative acute myocardial in-
farction (AMI), stroke, reoperation for bleeding and new
need for balloon counterpulsation and minor complica-
tions: pericardial drainage, new need for permanent pace-
maker, pneumonia, persistent atrial fibrillation (AF) andlate extubation. The influence of PPM on intensive care
unit (ICU) and total hospital stay was separately analyzed.
Echocardiographic assessment
All the patients underwent a complete M-mode, 2-
dimensional, and Doppler transthoracic echocardiog-
raphy before surgery. Left ventricular ejection fraction
was calculated using Simpson’s formula from biplane ap-
ical four and two chambers views. The severity of aortic
stenosis was graded by integration of Doppler methods,
continuity equation and planimetry and the degree of
aortic regurgitation was determined primarily by the
width of the regurgitant jet determined by color Doppler
and then calculating the regurgitant orifice area and
characterizing the reversed flows in descending aorta.
Surgical technique
All patients were approached through a standard full me-
dian sternotomy, under cardiopulmonary bypass with
moderate hypothermia. Myocardial protection was accom-
plished by antegrade and retrograde cristaloid cardioplegia
with CelsiorW solution (Genzyme, United States). The lar-
gest suitable prosthesis was always implanted in supra-
annular position using the specific manufacturer’s devices.
Valvular prostheses were implanted with mattress sutures
with teflon pledgets. The final decision as to the type of
prosthesis to be implanted was made by the surgeon at
the time of surgery taking into account the preoperative
characteristics and the intraoperative findings.
Statistical analysis
Shapiro-Wilk test was used to verify the normality of quan-
titative variables. Continuous variables were expressed as
mean± standard deviation or median (interquartile range),
as appropiate. Categorical variables were expressed as ab-
solute number (percentage). Comparisons of proportions
were performed using the χ2 test or Fisher’s exact test, as
appropriate. Group comparison for continuous variables
was tested with the Student’s unpaired T test in case of
normal distribution or Mann–Whitney U test otherwise.
Table 3 Characteristics of the surgical procedure
Without PPM With PPM p
Previous balloon counterpulsation 0 (0%) 1 (1,6%) 0,13
CPB time 68 (56–80) 76 (67–101) 0,004
Aortic cross-clamp time 54 (46–65) 62 (48–71) 0,032
Bioprosthesis 6 (4,3%) 14 (23%) <0,001
CPB: CARDIOPULMONAR BYPASS.
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tional reports, a propensity score (PS) analysis was under-
taken. This is the probability that PPM occurs in a patient
given his or her baseline and surgical characteristics. To
calculate PS we created a non-parsimonious logistic regres-
sion model where PPM acted as a dependent variable and,
as predictors, all the variables that differed according to
the PPM in the univariate analysis (Tables 2 and 3) and
those that, although did not differ, were considered clinic-
ally relevant. We verified the supposition of linearity for
the continuous variables and the lack of colinearity be-
tween the predictors. The discrimination and calibration of
the model were evaluated by area under the receiver oper-
ating characteristic curve and Hosmer-Lemeshow test for
goodness of fit.
Odds ratios (ORs) were calculated by a logistic regression
model for in-hospital outcomes with PPM as the exposure
variable and PS as the covariate. All analyses were stratifiedTable 2 Preoperative patient characteristics
Without PPM With PPM p
Age 61 (56–66) 64 (57–68) 0,046
Women 49 (35,5%) 18 (29,5%) 0,41
HT 77 (55,8%) 34 (55,7%) 0,99
DM 22 (15,9%) 15 (25%) 0,13
Hypercholesterolemia 70 (50,7%) 27 (44,3%) 0,4
BSA 1,82 ± 0,2 1,91 ± 0,16 0,002
BMI 28,84 ± 4,29 30,07 ± 4,27 0,086
Peripheral arterial disease 13 (9,4%) 11 (18%) 0,085
CPD 20 (14,5%) 11 (18%) 0,52
Previous stroke 4 (2,9%) 4 (6,6%) 0,22
Previous neurological dysfunction 4 (2,9%) 0 (0%) 0,18
Preoperative creatinine concentration 0,94 (0,8–1,09) 1 (0,86–1,17) 0,043
Previous AF 18 (13%) 7 (11,5%) 0,76
Previous AMI 1 (0,7%) 1 (1,6%) 0,55
LVD 16 (11,6%) 7 (11,5%) 0,98
SPHT 14 (10,1%) 9 (14,8%) 0,35
Peak transaortic pressure gradient 81 (70–91) 81 (71–93) 0,93
Associated aortic regurgitation 27 (19,6%) 16 (26,2%) 0,29
Emergency surgery 4 (2,9%) 1 (1,6%) 0,61
Logistic EuroSCORE 2,8 (2,1–4,6) 2,9 (2,1–5,1) 0,51
Previous pacemaker implantation 0 (0%) 2 (3,3%) 0,033
NYHA functional class III-IV 67 (48,6%) 30 (49,2%) 0,93
Etiology
Degenerative disease 90 (65,2%) 41 (67,2%) 0,78
Congenital disease 37 (26,8%) 13 (21,3%) 0,41
Rheumatic disease 11 (8%) 7 (11,5%) 0,43
HT: HYPERTENSION; DM: DIABETES MELLITUS; BSA: BODY SURFACE AREA; BMI:
BODY MASS INDEX; COPD: CHRONIC PULMONARY DISEASE; AF: ATRIAL
FIBRILLATION; AMI; ACUTE MYOCARDIAL INFARCTATION; LVD: LEFT
VENTRICULAR DYSFUNCTION; SPHT; SEVERE PULMONAR HYPERTENSION;
NYHA: NEW YORK HEART ASSOCIATION.by main surgeon and year of surgery. The Enter-method
was employed in all regression models and a two-sided p
value< 0,05 was considered statistically significant.
Definitions
Severe aortic stenosis: aortic valve area of less than 1 cm2,
mean gradient greater than 40 mmHg or jet velocity greater
than 4 m/s measured by preoperative echocardiography.
Left ventricular dysfunction (LVD): left ventricular ejec-
tion fraction< 50%.
Severe pulmonary hypertension (SPHT): systolic pul-
monary artery pressure> 50 mmHg.
Coronary artery disease: > 50% reduction in vessel
diameter in at least one angiographic plane.
Associated aortic regurgitation: concomitant grade III or
IV aortic regurgitation by transthoracic echocardiography.
Emergency surgery: the operation that is required within
24 hours since onset of symptoms due to unstable critical
status or life-threatening situation.
Chronic pulmonary disease: long term use of bronchodi-
lators or steroids for lung disease.
Peripheral arterial disease: carotid stenosis> 50%, clau-
dication or previous or planned intervention on the ab-
dominal aorta, limb arteries or carotids.
Postoperative period: that conducted during hospital
stay or 30 days after surgery if previously discharged.
Postoperative AMI: troponin T level≥1 ng/ml associated
with compatible electrocardiographic (usually new left
bundle branch block or new Q waves) and echocardio-
graphic findings.
Postoperative stroke: clinically compatible neurological
event that persists for at least 24 hours.
Persistent postoperative AF: atrial fibrillation at dis-
charge in patients with preoperative sinus rhythm.
Late extubation: carried out after the first 24 hours
post-surgery.
Prolonged ICU and total hospital stay: 75 percentile of
our series was selected (more than 3 days for ICU and
more than 11 days for total hospital stay).
Results
Patient characteristics and surgical data
During the study period, 199 patients met the inclusion
criteria. Sixty-seven (33,7%) were women and the me-
dian age was 62 (57–67) years old (Figure 1).
Figure 1 Age distribution at the time of surgery.
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their IEOA was 0,76 (0,71–0,81) versus 1,08 (0,95–1,19) in
the patients with no PPM. Only 6 (3%) patients had severe
PPM. As depicted in Table 2, patients with PPM were
older and had higher body surface area, higher preopera-
tive creatinine levels and greater proportion of previous
pacemaker. In addition, patients with PPM had longer car-
diopulmonary bypass and aortic cross-clamp times and
greater percentage of tissue valves implanted (Table 3).Table 4 Postoperative complications
Without PPM With PPM p
Major complications
Postoperative AMI 5 (3,6%) 5 (8,2%) 0,17
Postoperative stroke 0 (0%) 3 (4,9%) 0,009
Reintervention due to bleeding 4 (2,9%) 3 (4,9%) 0,47
New need for balloon counterpulsation 4 (2,9%) 9 (14,8%) 0,002
Minor complications
Pericardial drainage 2 (1,4%) 3 (4,9%) 0,15
Persistent AF 6 (5,1%) 3 (6%) 0,82
Pneumonia 5 (3,6%) 0 (0%) 0,13
New need for permanent pacemaker 4 (2,9%) 1 (1,6%) 0,6
Late extubation 12 (8,8%) 9 (15%) 0,19
AMI: ACUTE MYOCARDIAL INFARCTION; AF: ATRIAL FIBRILLATION.Postoperative mortality
Five patients (8,2%) with and one (0,7%) without PPM died
during the postoperative period (p=0,004). All deaths were
cardiac-related (three patients died due to myocardial in-
farction, two patients due to low cardiac output syndrome
with cardiogenic shock and one due to sudden death in
hospital ward). No patient died between discharge and
postoperative day 30.
The following variables were included for PS model con-
struction: age, gender, hypertension, BSA, emergency
surgery, previous pacemaker, preoperative creatinine
concentration, peak transaortic pressure gradient, LVD,
associated aortic regurgitation, III-IV New York Heart
Association (NYHA) functional class, cardiopulmonary by-
pass time, aortic cross-clamp time, type of prosthesis,
main surgeon and year of surgery. The estimated PS
showed good discrimination power (C statistic = 0,78; 95%
CI= 0,71–0,85) and calibration characteristics (χ2 = 4,95;
p=0,76) After adjusting for PS, PPM was a strong predictor
of postoperative mortality (OR=8,71; 95% CI=1,67–45,29;
p=0,04).Postoperative complications and stay
Table 4 shows postoperative complications of patients
with and without PPM. When compared with patients
with no PPM, patients with PPM had more percentage
of postoperative stroke and new need for balloon coun-
terpulsation. Total hospital stay was 9 (7–11) days for
patients with PPM and 9 (7–11) days for patients with-
out PPM (p= 0,91). ICU stay was 2 (1–3) for patients
with PPM and 2 (1–3) for those with no PPM (p= 0,73).
After adjusting for PS, PPM was an independent pre-
dictor for major postoperative complications (OR= 2,96;
CI = 1,03–8,55; p= 0,044) but not for minor complica-
tions (OR= 0,61; CI = 0,23–1,6; p= 0,31). In addition,
PPM did not show influence on prolonged ICU stay
(OR= 0,65; CI = 0,32–1,34; p= 0,24) or prolonged total
hospital stay (OR= 0,91; CI = 0,43–1,91; p= 0,81).
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The incidence of PPM in our single-centre cohort of
young and middle-aged patients who underwent AVR
for SAS was 30,7%. Although this is in line with the rates
reported on some studies [4,9], these results are highly
variable in the literature being present in 19–70% of
patients [2]. In addition, the influence of PPM on the
outcomes of patients undergoing AVR is unknown and
remains controversial. Several reasons could be argued
to explain these diverging results.
First, different methods have been used for PPM calcula-
tion. Recently, in vivo EOA measurements are increasingly
being selected for this purpose, but some reference authors
[5,7] still use ex vivo manufacturer reported EOA values,
with the limitations derived from this fact [11]. Secondly,
contemporary standard AVR offers excellent early and late
clinical outcomes with a low incidence of adverse events
which makes it difficult to see differences. And finally, the
heterogeneity of the population previously studied, so most
previous reports have studied patients with other valvular
diseases, ascending aortic aneurysms or concomitant by-
pass grafting.
It has recently been suggested that the impact of PPM
could be influenced by patient baseline conditions. So,
some researchers are focusing on identifying those patients
who are more vulnerable to the clinical consequences of
PPM. Mohthy et al. [8] and Moon et al. [9] have found a
significant negative effect of PPM on late survival in
patients< 70 and< 60 years old respectively. However, at
our knowledge no previous reports have studied in young
patients the impact of PPM on mortality and morbidity
during the early postoperative course which is probably the
most vulnerable period for the left ventricle [2].
Impact of PPM on early mortality
Although it is of utmost importance to assess the impact
of PPM on early mortality after AVR, findings across
several studies show conflicting results. This is often due
to the wide heterogeneity between studies. As aforemen-
tioned, there are at least 2 different mismatch entities
(severe and moderate PPM), several parameters used to
calculate PPM (in vivo or ex vivo EOA values) and sev-
eral cut-off points to consider its existence.
Bridges et al. [20] published the largest study on PPM,
which analyzed data acquired from a total of 42.310 patients
undergoing isolated AVR. Small EOA were reported to be
associated with increased operative mortality, but among
patients receiving the same prosthesis model and size, those
patients with a larger BSA had better outcomes. It was
speculated that the impact of PPM on short term mortality
may be less important than several unmeasured confound-
ing variables, including the BSA.
Urso et al. [6] have recently reviewed the concept of
mismatch as a risk factor for early and mid-term mortalityafter AVR. These authors found no association between
PPM and early outcomes. However, it should be noted
that the patient population was elderly with a median age
of 72. Other authors as Blais et al. [4] or Rao et al. [5]
studied large series of patients undergoing AVR and found
that PPM was a significant predictor of early mortality.
Our findings, in a consecutive series of 199 young and
middle-aged patients (median age of 62 years) with a low
early mortality rate, suggest that even moderate PPM,
negatively impact on early postoperative survival after iso-
lated AVR for SAS.Impact of PPM on postoperative complications
Although mortality is the most important postoperative ad-
verse outcome, lower morbidity rates are essential for ad-
equate patient recovery and quality of life. In fact, the
presence of excellent perioperative outcomes after AVR,
factors possibly affecting the longer term functionality gain
more and more importance. Our study showed that in
young patients undergoing AVR, PPM is associated with
major complications, mostly at the expense of postoperative
stroke and new need for balloon counterpulsation. In this
sense, Nozohoor et al. [7] reported that PPM was a pre-
dictor of postoperative neurological events in general popu-
lation undergoing surgery. The authors argue possible
reasons for this finding, such as a more cumbersome surgi-
cal procedure in those patients with small aortic annuli and
extensive calcification who are prone to PPM. In addition,
the increased post-prosthetic turbulence may induce rup-
ture of calcified plaques with subsequent embolization.
However, Yap et al. [21] did not find an association between
PPM and stroke, prolonged ventilation and prolonged ICU
or hospital stay.
Our study failed to demonstrate significant association
between PPM and prolonged hospital stay. An underpow-
ered analysis or the absence of differences in minor com-
plications could have played a key role in this finding.
Moreover, further studies with larger number of patients
will be necessary to define which specific complications are
related to PPM.Clinical implications
The major finding of this study is that PPM is an import-
ant and independent risk factor for short-term mortality
in young and middle-aged patients undergoing AVR. The
practical implications of these findings are important given
that PPM is not a rare occurrence with a prevalence in the
literature between 19 and 70% [2,19,22].
Furthermore, as opposed to other predictors of short-
term mortality, moderate-severe PPM can be largely
avoided with the use of a proper preventive strategy at
the time of operation [19,22,23].
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Several limitations should be noted. This is a single-center
study and results extrapolation must be cautiously consid-
ered. In addition, this study is retrospective and has limita-
tions inherent to its nature. Moreover, the sample size is
relatively small with few adverse clinical events and there-
fore, a random change in one of them could possibly modify
the final results.
Conclusions
Although severe PPM is rare, moderate mismatch is a com-
mon finding in the young and middle-aged patient under-
going AVR for SAS. Our results suggest that, even when
moderate, the presence of PPM confers a worse short-term
prognosis, both in terms of perioperative complications and
mortality. Consequently, preventive surgical strategies are
strongly recommended for this patient population.
Abbreviation
SAS: Severe aortic stenosis; AVR: Aortic valve replacement; PPM: Patient-
prosthesis mismatch; I/EOA: Indexed/Effective orifice area; BSA: Body surface
area; PS: Propensity score.
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